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The purpose of this study was to compare the parameters of the dose–volume histogram (DVH) between
proton beam therapy (PBT) and X-ray conformal radiotherapy (XCRT) for locally advanced non-small-cell
lung cancer (NSCLC), according to the tumor conditions. A total of 35 patients having NSCLC treated with
PBT were enrolled in this analysis. The numbers of TNM stage and lymph node status were IIB (n = 3), IIIA
(n = 15) and IIIB (n = 17), and N0 (n = 2), N1 (n = 4), N2 (n = 17) and N3 (n = 12), respectively. Plans for
XCRT were simulated based on the same CT, and the same clinical target volume (CTV) was used based on
the actual PBT plan. The treatment dose was 74 Gy-equivalent dose (GyE) for the primary site and 66 GyE for
positive lymph nodes. The parameters were then calculated according to the normal lung dose, and the irradi-
ation volumes of the doses (Vx) were compared. We also evaluated the feasibility of both plans according to
criteria: V5 ≥ 42%, V20 ≥ 25%, mean lung dose ≥ 20 Gy. The mean normal lung dose and V5 to V50 were sig-
nificantly lower in PBT than in XCRT. The differences were greater with the more advanced nodal status and
with the larger CTV. Furthermore, 45.7% of the X-ray plans were classified as inadequate according to the cri-
teria, whereas 17.1% of the proton plans were considered unsuitable. The number of inadequate X-ray plans
increased in cases with advanced nodal stage. This study indicated that some patients who cannot receive
photon radiotherapy may be able to be treated using PBT.
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INTRODUCTION
Radiotherapy plays an important role in the treatment of
locally advanced, unresectable non-small-cell lung cancer
(NSCLC). In order to achieve the maximum survival benefit
with radiotherapy, the dose–response relationship and its
combination with chemotherapy has been investigated since
the 1980s. Several successful dose-escalation studies with
concurrent chemotherapy have been undertaken worldwide
and have led to improved tumor control and survival at doses
above 70 Gy [1–8]. However, the Phase III study by RTOG
showed no survival benefit with a dose of 74 Gy compared
with 60 Gy [9]. While Cox et al. reported that pulmonary or
cardiopulmonary effects of radiotherapy could affect the
outcome, the reason for this was unclear [10]. Meanwhile,
Chang et al. successfully administered chemo-proton therapy
for unresectable Stage III NSCLC with a dose of 74 GyE, and
reported a median survival time of 29.4 months [11]. We con-
sider that PBT will be key to safe dose escalation for locally
advanced NSCLC due to the sharp energy peak, called the
Bragg peak.
The dosimetric comparison of protons and photon radio-
therapy for early stage NSCLC has been widely discussed,
and some reports of early-stage NSCLC have shown that
PBT also significantly reduces the normal lung dose
[12–17]. However, there have been few investigations of the
differences in dose distribution for advanced NSCLC
[17, 18].
In this report, we simulated proton therapy using a high radi-
ation dose at 74 GyE for unresectable locally advanced
NSCLC and compared the parameters of the dose–volume his-
tograms (DVHs) for PBT and photon conformal radiotherapy
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(XCRT), based upon the tumor condition, i.e. stage, lymph
node status, and target volume.
MATERIALS ANDMETHODS
Patient characteristics
A total of 35 cases of inoperable locally advanced Stage IIB
and III NSCLC were enrolled in this analysis. The TNM
stage was Stage IIB in three patients, IIIA in 15, and IIIB in
17. The nodal stage was N0, N1, N2 and N3 in 2, 4, 17 and
12 patients, according to the TNM classification of malig-
nant tumors, sixth edition. The tumor was located in the
upper lobe in 24 patients and in the middle and lower lobe in
11 patients. All patients were treated with proton beams of
155–250 MeV generated using a synchrotron accelerator
(Hitachi Inc., Ibaraki, Japan) at the Proton Medical Research
Center. This study was approved by our institutional review
board, and written informed consent was obtained from all
patients.
Treatment planning
For treatment planning, chest CT images were obtained in
5-mm thick slices, with the patient in a body cast in the treat-
ment position (Engineering System Co., Matsumoto, Japan),
during the end-expiratory phase using a respiratory-gated
system (DAR-3000, Shimadzu, Kyoto, Japan). The dose cal-
culation for PBT and XCRT was performed using the same
CT series for each patient with the pencil beam method for
PBT (proton treatment planning software ver. 2, Hitachi Inc.,
Ibaraki, Japan) and with superposition on for XCRT (Xio
ver. 4, Elekta, Stockholm, Sweden). Proton beams of 155–
250 MeV and X-ray irradiation of 10 MV were used in the
treatment plans. The treatment planning system for PBT
automatically estimated the conditions required for beam
delivery, which include a ridge filter, a range shifter, a colli-
mator and bolus. The beam delivery system created a homo-
geneous dose distribution at the prescription dose using the
spread-out Bragg peak of the proton beams. The concept of
dose delivery, for both the target and normal tissues, was
exactly the same for PBT as for XCRT; the daily fraction-
ation dose was 2 Gy, and the primary site and positive lymph
nodes were irradiated at 74 Gy and 66 Gy, respectively.
We defined the clinical target volume (CTV) as the pri-
mary tumor and clinically positive lymph nodes. Prophylac-
tic lymph nodes were not included in the CTV. Clinically
positive lymph nodes were defined as nodes ≥1 cm as visua-
lized on a CT scan or as PET-positive lymph nodes. CTV-p
was defined as the primary tumor alone. The planned target
volume (PTV) and PTV-p encompassed the CTV and
CTV-p, respectively, with a 5–10-mm margin in all direc-
tions and an additional 5-mm margin in the caudal direction
(to compensate for respiratory motion), and the coverage of
PTVs was provided for by more than 95% prescribed
doses. To ensure this coverage, we set up ~5-mm distal and
proximal margins for PTVs at PBT. The total normal lung
volume was the total lung volume reduced by the tumor
volume (gross tumor volume: GTV) and atelectasis. The
median CTV was 228.5 cm3 (range: 34.4–555.5 cm3), and the
median total normal lung volume was 3426.4 cm3 (range:
1219–5179 cm3).
For PBT, both 66 GyE and an additional 8 GyE were
delivered via two to three ports in the optimal direction to
maintain a tolerable spinal dose (~40 GyE) to PTV and
PTV-p, respectively. For XCRT, an initial 44 Gy dose was
delivered via the anterior and posterior ports for PTV, and
22 Gy was then irradiated using oblique fields to avoid the
spinal cord. Finally, we applied a booster dose at 8 Gy to
PTV-p. A typical treatment plan of XCRT and PBT is shown
in Fig. 1.
Analysis
The DVH of the lung was calculated during planning for
both PBT and XCRT, and the relationship between tumor
factor (TNM stage, T stage, N stage, CTV) and dosimetric
factors (i.e. mean lung dose (MLD) and the percentage
volume of the whole lung receiving more than a certain dose
(Vx)) were analyzed by a two-sample t-test and the correl-
ation coefficient. We also evaluated the feasibility of the
plans according to the criteria reported for the increasing
risk of radiation pneumonitis, as follows: V5 ≥ 42% [19],
V20 ≥ 25% [20],MLD ≥ 20 Gy [21].
All statistical analyses were performed using statistical
software (SPSS, IBM Inc., NY, USA), and P-values < 0.05
were considered statistically significant.
RESULTS
Mean lung dose
The relationship between the MLD and lymph node status or
stage is shown in Fig. 2. The average MLD for N0–1, N2,
N3 in PBT and XCRT was 7.80 Gy vs 12.25 Gy (P = 0.01),
10.41 Gy vs 14.17 Gy (P < 0.001), and 12.20 Gy vs 18.00
Gy (P < 0.001), and the average MLD for Stage IIB,
IIIA and IIIB was 9.05 Gy vs 11.61 Gy (P = 0.07), 9.70 Gy
vs 13.68 Gy (P < 0.001) and 11.62 Gy vs 17.08 Gy
(P < 0.001), respectively. The MLD in the PBT was signifi-
cantly lower than that of XCRT for all stages and nodal
status. The CTV volume was also a significant factor affect-
ing MLD (coefficient factor (r) = 0.376, P = 0.013) (Fig. 3).
The larger the CTV, the greater the difference in MLD
between the PBT and the XCRT plans.
Lung volume receiving more than a certain
dose (Vx)
The results of V5, V10, V20, V30, V40 and V50 in accord-
ance with nodal stages are shown in Fig. 4. The irradiated
normal lung volume increased significantly with the
advanced nodal stage. Furthermore, in Fig. 4, both lines in
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the PBT and XCRT appear to be nearly parallel in the N0 to
N2 patients, but not in the N3 patients. This means that the
differences in the lung doses between the XCRT and PBT
are greater in the N3 patients compared with the N0–2
patients, especially for the dose to the lower to middle lung
lobes. The irradiated normal lung volume also increased
significantly with the advanced TNM stage (Fig. 5). The cor-
relation between CTV and the differences in Vx (Vx in XCRT
– Vx in PBT) was also observed in V30–V50 (P = 0.391,
0.454, 0.266, 0.046, 0.019 and 0.030 for V5, V10, V20,
V30, V40 and V50, respectively). Thus, the differences
between PBT and XCRT were observed, and while the
differences were greater at lower doses, the correlation of
Vx differences with CTV was stronger for larger doses;
i.e. V30–V50.
Feasibility of the plan
Table 1 summarizes the number of inadequate plans for
photon radiotherapy and PBT. According to the criteria of
V5 ≥ 42% [19], V20 ≥ 25% [20] and MLD ≥ 20 Gy([21],
Fig. 1. Comparison of dose distributions for T1N3M0 lung cancer between XCRT (A/B) and PBT (C/D). (A) An initial
44 Gy of XCRT was delivered via the anterior and posterior ports. Note the difference in dose to the spinal cord between
XCRT and PBT. (B) Sum plan of XCRT. After 44 Gy, an oblique field was needed to avoid the spinal cord in XCRT. (C) In
PBT, a reduction of the dose to the spinal cord to less than 50% allows using the anterior and posterior ports until 66 GyE to
the CTV1. (D) Sum plan of PBT.
Fig. 2. The relationship between the mean lung dose and N stage for each modality of PBT and XCRT.
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45.7% of the XCRT plans were classified as inadequate,
whereas only 17.1% of the proton plans were not suitable.
The number of inadequate XCRT plans increased according-
ly with the advanced nodal stage.
DISCUSSION
Radiation pneumonitis is a significant concern during radio-
therapy for patients with lung cancer. The risk of radiation
pneumonitis correlates closely with the volume dose of the
normal lung. Tsujino et al. found that V20 correlated signifi-
cantly with the incidence of radiation pneumonitis. They
reported that the incidence of severe radiation pneumonitis
was significantly higher in patients with V20 ≥ 25% [20].
Marks et al. analyzed the findings of previous studies and
suggested that an MLD of 20–23 Gy with conventional frac-
tions was appropriate to limit the risk of radiation pneumon-
itis to ≤ 20% [21]. Furthermore, Wang et al. analyzed
patients with NSCLC that were treated with concurrent che-
moradiotherapy and showed a significantly lower frequency
of Grade 3 or worse radiation pneumonitis for patients with
V5 ≤ 42% compared with those patients with V5 > 42% [19].
Therefore, radiotherapy can be more difficult for larger
tumors, with increasing risk of radiation pneumonitis in the
treatment of locally advanced NSCLC.
Chemoradiotherapy is now standard treatment for unre-
sectable locally advanced NSCLC. However, the feasible
doses for concurrent chemoradiotherapy remain controver-
sial. Even though a Phase III study (RTOG 0617) was not
able to show any survival benefit by dose escalation, the
toxicities were considered tolerable, and survival was
improved in many prospective studies [1–3, 8].
Meanwhile, proton beams are now popular for various
cancers because of their excellent dose localization, and they
can be applied to many patients with a variety of malignan-
cies. Some authors have reported favorable results for PBT
for advanced NSCLC [22–24]. Chang et al. reported that the
median survival for patients with Stage III NSCLC was 29.4
months with concurrent chemo–proton therapy using a dose
of 74 GyE, with no Grade 4 non-hematologic toxicities [22].
Oshiro et al. reported that while the median survival was
21.3 months, Grade ≥ 3 lung toxicities were observed in
three patients, and no severe esophagitis was observed in the
standalone PBT for 57 patients with Stage III NSCLC [24].
These results suggest that PBT has a great potential for pro-
ducing a survival benefit with less toxicities, which may be a
Fig. 3. The correlation between CTV1 and the reduction in MLD.
Difference in MLD =MLD (XCRT) −MLD (PBT).
Fig. 4. The relationship between V5–50 and N stage for each modality of PBT and XCRT.
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result of its excellent dose localization, as noted above. To
the best of our knowledge, there have only been two reports
suggesting dosimetric advantages for PBT in advanced
NSCLC. Chang et al. compared dose distribution in XCRT
(63 Gy) with PBT (74 GyE) plans and reported that V5,
V10 and V20 were significant lower in PBT plans. Stuschke
et al. compared intensity-modulated proton therapy (IMPT),
photon intensity-modulated radiotherapy (IMXT) and tomo-
therapy in six patients and found that MLD and V10 and
V20 were lowest for the IMPT plans [18]. Our study also
showed dosimetric advantages of proton compared with
photon radiotherapy in the treatment of advanced NSCLC,
especially for more advanced lymph node stages, and some
patients who received PBT could not be treated with photon
radiotherapy. Furthermore, a significant correlation was
revealed between the CTV and MLD, V30, V40 and V50 in
our study, which suggested that PBT is more advantageous
for a larger CTV to reduce doses to the normal lung, espe-
cially for critical doses >20 Gy. Thus, PBT appears to
be more advantageous for patients with more advanced
NSCLC, and can provide treatment opportunities for some
patients with fewer options.
However, there are some limitations to our study. While
DVHs were investigated in the initial plan, some plans were
changed practically as a consequence of tumor shrinking.
Furthermore, the calculation algorithm differed between PBT
and photon radiotherapy in this study. Our results reflect a
practical propensity for a dose–volume relationship, but com-
parison of adoptive plans after refinement (using a Monte
Carlo algorithm) will be necessary for precise analysis in the
future.
In conclusion, PBT can reduce the normal lung dose com-
pared with XCRT, especially in the advanced nodal stage,
and more locally advanced patients can be treated by this
modality using PBT.
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